Latest revenue
$78.36B
as of 2026-03-31
Latest net income
$1.64B
as of 2026-03-31
Net margin
2.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $53.49B
- Enterprise value
- $59.66B
- P/E (trailing)
- 34.4×
- Forward P/E
- —
- P/B
- 28.03×
- Dividend yield
- 0.9%
- 52-wk high
- $377.54
- 52-wk low
- $244.82
- Beta
- —
- Shares out
- 194.6M
5-year trend
What this company does
Cencora is one of the largest pharmaceutical wholesalers in the US, buying drugs from manufacturers and distributing them to pharmacies, hospitals, and clinics. The company generates nearly all of its $86 billion quarterly revenue from drug distribution, earning thin margins (roughly 3.6% gross) on massive volumes. Cencora just reorganized into U.S. Healthcare Solutions and International Healthcare Solutions segments and is exploring strategic alternatives for MWI Animal Health, Profarma, and parts of PharmaLex, signaling a portfolio cleanup toward core human-health distribution.
Generated from COR's filing dated 2025-11-25
Key risks
- Opioid litigation overhang: $3.87 billion accrued litigation liability remains on the balance sheet as of December 31, 2025.
- Asset impairments: $249.5 million goodwill/asset impairment charge taken this quarter, signaling potential weakness in recently reorganized 'Other' segment businesses under strategic review.
- Thin margins amplify risk: gross margin only 3.6% on $85.9B revenue; small disruptions in drug pricing or customer mix can materially hit earnings.
Generated from COR's filing dated 2025-11-25
Profitability
Gross margin
3.6%
6.0%Operating margin
0.8%
10.5%Net margin
0.5%
5.8%Return on equity
103.1%
55.9%Return on assets
2.0%
9.8%Leverage
Debt / equity
49.79×
51.6%Long-term debt / equity
5.00×
15.2%Debt / assets
98.0%
1.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $78.36B | +3.8% | $1.64B | +128.6% | 2.1% |
Q4 2025 2025-12-31 | $85.93B | +5.5% | $559.6M | +14.5% | 0.7% |
Q3 2025 2025-09-30 | $83.73B | +5.9% | $-339.7M | -10144.5% | -0.4% |
Q2 2025 2025-06-30 | $80.66B | +8.7% | $687.4M | +42.2% | 0.9% |
Q1 2025 2025-03-31 | $75.45B | +10.3% | $717.9M | +70.6% | 1.0% |
Q4 2024 2024-12-31 | $81.49B | +12.8% | $488.6M | -18.8% | 0.6% |
Q3 2024 2024-09-30 | $79.05B | — | $3.4M | — | 0.0% |
Q2 2024 2024-06-30 | $74.24B | +10.9% | $483.5M | +0.8% | 0.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122
Your notes
Keep private notes on COR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$42.4M
Net activity
−$42.4M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns COR
Institutional value
$12.38B
Total shares held
42.9M
Distinct holders
762
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Boston Partners | 4.5M | $1.41B | — | New |
| 2 | Invesco Ltd. | 4.0M | $1.25B | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 1.5M | $486.6M | — | New |
| 4 | Mitsubishi UFJ Asset Management Co., Ltd. | 1.4M | $427.1M | — | New |
| 5 | WELLS FARGO & COMPANY/MN | 1.3M | $418.7M | — | New |
| 6 | Legal & General Group Plc | 1.3M | $412.4M | — | New |
| 7 | Mawer Investment Management Ltd. | 1.0M | $323.9M | — | New |
| 8 | Bank of New York Mellon Corp | 1.0M | $323.0M | — | New |
| 9 | DEUTSCHE BANK AG\ | 891.1K | $279.9M | — | New |
| 10 | Nuveen, LLC | 845.5K | $265.6M | — | New |
| 11 | Sumitomo Mitsui Trust Group, Inc. | 803.5K | $252.4M | — | New |
| 12 | UBS Group AG | 773.0K | $242.8M | — | New |
| 13 | FEDERATED HERMES, INC. | 749.6K | $235.5M | — | New |
| 14 | National Pension Service | 709.8K | $223.0M | — | New |
| 15 | TD ASSET MANAGEMENT INC | 704.1K | $221.2M | — | New |
| 16 | Swedbank AB | 594.7K | $186.8M | — | New |
| 17 | HSBC HOLDINGS PLC | 557.5K | $175.0M | — | New |
| 18 | Swiss National Bank | 540.9K | $169.9M | — | New |
| 19 | ENVESTNET ASSET MANAGEMENT INC | 502.9K | $158.0M | — | New |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 501.1K | $157.4M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Operating cash flow was negative $2.3B with inventories up $3.5B sequentially—what specific manufacturer or GLP-1 dynamics drove this build, and when does it reverse?
- 2
You booked a $249M goodwill/asset impairment this quarter—which reporting unit, and what assumptions changed versus the prior fair value test?
- 3
DSA expenses jumped 22% YoY to $1.80B, far outpacing 5.5% revenue growth—how much is sustainable run-rate versus one-time, and what's the FY26 margin trajectory?
Refreshed when COR files a new report · last from 2025-11-25